REFERENCES
- Waller PC, Coulson RA, Wood SM (1996) Regulatory pharmacovigilance in the United Kingdom: current principles and practice. Pharmacoepidemiol Drug Safety 5: 363–75.
- Wong ICK (1999) Pharmacovigilance resources in the United Kingdom. Pharm J 263: 285–8.
- Weber JCP (1984) Epidemiology of adverse reactions to nonsteroidal antiinflammatory drugs. Adv Inflammation Res 6: 1–7.
- Tamminga CA, Mack RA, Granneman GR et al (1997) Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety. Int Clin Psychopharmacol 12 (</b>suppl 1): 29–35.
- H. Lundbeck A/S, Copenhagen, Denmark. Data on file.
- Wehnert A (1998) The European Post-marketing Observational Serdolect1(EPOS) project: increasing our understanding of schizophrenia therapy. Int Clin Psychopharmacol 13 (suppl 3): 27–30.
- Sturkenboom MCJM, Picelli G, Moore N (2001) Mortality during use of sertindole and other anti-psychotics in The Netherlands and Belgium. Pharmacoepidemiol Drug Safety 10: S1-164. Abstract 273.
- Jablensky A (1995) Schizophrenia: the epidemiological horizon. In: Hirsch SR, Weinberger DR (eds) Schizophrenia, Chapter 13: 206–52.
- The World Health Report 2002, WHO, ISBN 924 1562072.
- Moore N, Lagnaoui R, Toumi M, Bégaud B (1999) Suicide and sudden death during treatment with atypical neuroleptics: a comparison of sertindole, olanzapine and risperidone. Schiz Res 36: 356–57.
- Mackay FJ, Wilton LV, Pearce GL et al (1998) The safety of risperidone: a post-marketing study on 7684 patients. Hum Psychopharmacol Clin Exp 13: 413 -18.
- Wilton LV, Heeley EL, Pickering RM, Shakir SA (2001) Comparitive study of mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine. J Psychopharmacol 15: 120–6.